Published in Science on February 14, 2008
Medication treatment of different types of alcoholism. Am J Psychiatry (2010) 2.69
Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol (2010) 1.93
Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther (2012) 1.64
Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. Pharmacol Ther (2010) 1.62
Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol (2012) 1.56
Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev (2014) 1.40
Translational and reverse translational research on the role of stress in drug craving and relapse. Psychopharmacology (Berl) (2011) 1.33
Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov (2009) 1.30
Neurobiology of alcohol dependence: focus on motivational mechanisms. Alcohol Res Health (2008) 1.29
Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev (2009) 1.18
Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress. Neuropsychopharmacology (2015) 1.17
Neuroimmune pathways in alcohol consumption: evidence from behavioral and genetic studies in rodents and humans. Int Rev Neurobiol (2014) 1.17
Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity. Pharmacol Biochem Behav (2012) 1.13
Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Front Psychiatry (2013) 1.10
Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropsychopharmacology (2011) 1.08
Stress-related neuropeptides and addictive behaviors: beyond the usual suspects. Neuron (2012) 1.06
Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS Neurol Disord Drug Targets (2010) 1.06
Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend (2013) 1.03
A differential role for neuropeptides in acute and chronic adaptive responses to alcohol: behavioural and genetic analysis in Caenorhabditis elegans. PLoS One (2010) 1.02
Alcohol dependence, withdrawal, and relapse. Alcohol Res Health (2008) 0.99
Ethanol-enhanced GABA release: a focus on G protein-coupled receptors. Brain Res Rev (2010) 0.98
NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD. J Psychopharmacol (2009) 0.97
Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach. Neuroimage (2011) 0.97
The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects. Neuropsychopharmacology (2016) 0.97
Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. Psychopharmacology (Berl) (2011) 0.96
The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology (2015) 0.96
The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. PLoS One (2010) 0.96
Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice. Psychopharmacology (Berl) (2010) 0.96
Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety. J Pharmacol Exp Ther (2010) 0.95
An acute psychosocial stressor increases drinking in non-treatment-seeking alcoholics. Psychopharmacology (Berl) (2011) 0.95
Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology (2009) 0.94
A novel role for PSD-95 in mediating ethanol intoxication, drinking and place preference. Addict Biol (2011) 0.93
Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J Immunol (2011) 0.92
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence. Neuropsychopharmacology (2016) 0.90
An acute psychosocial stressor does not potentiate alcohol cue reactivity in non-treatment-seeking alcoholics. Alcohol Clin Exp Res (2010) 0.90
Methods for inducing alcohol craving in individuals with co-morbid alcohol dependence and posttraumatic stress disorder: behavioral and physiological outcomes. Addict Biol (2014) 0.88
The NK1 receptor antagonist L822429 reduces heroin reinforcement. Neuropsychopharmacology (2012) 0.88
Nicotine enhances excitability of medial habenular neurons via facilitation of neurokinin signaling. J Neurosci (2014) 0.88
Tacr1 gene variation and neurokinin 1 receptor expression is associated with antagonist efficacy in genetically selected alcohol-preferring rats. Biol Psychiatry (2013) 0.88
Genetic association of the tachykinin receptor 1 TACR1 gene in bipolar disorder, attention deficit hyperactivity disorder, and the alcohol dependence syndrome. Am J Med Genet B Neuropsychiatr Genet (2014) 0.87
Medications for unhealthy alcohol use: across the spectrum. Alcohol Res Health (2011) 0.85
Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol (2012) 0.84
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol (2010) 0.84
Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils. Behav Pharmacol (2009) 0.84
The role of the neurokinin-1 receptor in stress-induced reinstatement of alcohol and cocaine seeking. Neuropsychopharmacology (2013) 0.82
Substance P inhibits GABAB receptor signalling in the ventral tegmental area. J Physiol (2010) 0.81
Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models. Addict Biol (2016) 0.80
Neurochemical and neurostructural plasticity in alcoholism. ACS Chem Neurosci (2012) 0.79
The detrimental effects of emotional process dysregulation on decision-making in substance dependence. Front Integr Neurosci (2012) 0.79
Molecular basis of alcoholism. Handb Clin Neurol (2014) 0.78
Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Res Health (2008) 0.78
The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study. Psychopharmacology (Berl) (2014) 0.77
Genetic and environmental determinants of stress responding. Alcohol Res (2012) 0.77
Deficits in substance P mRNA levels in the CeA are inversely associated with alcohol-motivated responding. Synapse (2009) 0.77
A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction. Int Rev Neurobiol (2016) 0.77
Increased neurokinin-1 receptor availability in the amygdala in social anxiety disorder: a positron emission tomography study with [(11)C]GR205171. Transl Psychiatry (2015) 0.77
The pharmacology of neurokinin receptors in addiction: prospects for therapy. Subst Abuse Rehabil (2015) 0.77
Dysregulation of Brain Stress Systems Mediates Compulsive Alcohol Drinking. Curr Opin Behav Sci (2016) 0.77
Treatment of alcohol dependence with drug antagonists of the stress response. Alcohol Res (2012) 0.76
Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders. Front Neurosci (2014) 0.76
Focus on: Neuroscience and treatment: the potential of neuroscience to inform treatment. Alcohol Res Health (2010) 0.76
Substance use modulates stress reactivity: Behavioral and physiological outcomes. Physiol Behav (2016) 0.76
Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward. Psychopharmacology (Berl) (2016) 0.76
Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography. Int J Neuropsychopharmacol (2014) 0.75
Neurokinin 1 receptor blockade in the medial amygdala attenuates alcohol drinking in rats with innate anxiety but not in Wistar rats. Br J Pharmacol (2015) 0.75
Introduction to the special issue "Pharmacotherapies for the treatment of alcohol abuse and dependence" and a summary of patents targeting other neurotransmitter systems. Recent Pat CNS Drug Discov (2012) 0.75
Substance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation. J Neurophysiol (2015) 0.75
Delta Opioid Pharmacology in Relation to Alcohol Behaviors. Handb Exp Pharmacol (2016) 0.75
Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers. Br J Clin Pharmacol (2013) 0.75
Neurokinin 1 and opioid receptors: relationships and interactions in nervous system. Transl Perioper Pain Med (2016) 0.75
Addiction research centres and the nurturing of creativity: the National Institute on Alcohol Abuse and Alcoholism. Addiction (2010) 0.75
Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics. Prog Brain Res (2015) 0.75
Adrenocortical sensitivity, moderated by ongoing stress, predicts drinking intensity in alcohol-dependent men. Psychoneuroendocrinology (2016) 0.75
Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis. J Neuroinflammation (2017) 0.75
Substance P in the anterior thalamic paraventricular nucleus: promotion of ethanol drinking in response to orexin from the hypothalamus. Addict Biol (2015) 0.75
The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description. J Psychopharmacol (2016) 0.75
Bidirectional relationship between alcohol intake and sensitivity to social defeat: association with Tacr1 and Avp expression. Addict Biol (2017) 0.75
Pain in knee osteoarthritis is associated with variation in the neurokinin 1/substance P receptor (TACR1) gene. Eur J Pain (2017) 0.75
A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI. Neuroimage (2003) 4.85
1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet (2003) 4.41
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology (2002) 3.79
A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry (2007) 3.10
Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci (2002) 2.94
Progression of fibrosis in chronic hepatitis C. Gastroenterology (2003) 2.77
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci (2003) 2.37
Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence. Biol Psychiatry (2007) 2.29
Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. FASEB J (2002) 2.29
Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat Neurosci (2002) 2.24
The SH3 binding motif of HCV [corrected] NS5A protein interacts with Bin1 and is important for apoptosis and infectivity. Gastroenterology (2006) 1.89
Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology (2003) 1.87
Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci U S A (2009) 1.82
The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry (2010) 1.80
Inhibition of the amygdala: key to pathological states? Ann N Y Acad Sci (2003) 1.78
Local translation in primary afferent fibers regulates nociception. PLoS One (2008) 1.70
Further exploring the brain-skin connection: stress worsens dermatitis via substance P-dependent neurogenic inflammation in mice. J Invest Dermatol (2007) 1.67
Corticotrophin releasing factor-induced synaptic plasticity in the amygdala translates stress into emotional disorders. J Neurosci (2004) 1.67
Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology (2005) 1.66
Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. J Neurosci (2012) 1.65
Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse. Pharmacol Ther (2010) 1.62
Reg2 inactivation increases sensitivity to Fas hepatotoxicity and delays liver regeneration post-hepatectomy in mice. Hepatology (2006) 1.61
A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J Neurosci (2009) 1.58
Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend (2008) 1.57
Medications development to treat alcohol dependence: a vision for the next decade. Addict Biol (2012) 1.56
Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proc Natl Acad Sci U S A (2008) 1.56
Spinal-supraspinal serotonergic circuits regulating neuropathic pain and its treatment with gabapentin. Pain (2005) 1.54
Amphetamine modulates human incentive processing. Neuron (2004) 1.52
Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry (2007) 1.50
Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain (2005) 1.49
Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology (2008) 1.43
Quantitation of cannabinoid CB1 receptors in healthy human brain using positron emission tomography and an inverse agonist radioligand. Neuroimage (2009) 1.42
[Researchers and psychiatrists defending Gillberg's research on ADDH: Karfve's campaign is a form of personal persecution and scientific basis is missing]. Lakartidningen (2003) 1.39
A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication. J Stud Alcohol (2003) 1.39
A role for transcriptional repressor methyl-CpG-binding protein 2 and plasticity-related gene serum- and glucocorticoid-inducible kinase 1 in the induction of inflammatory pain states. J Neurosci (2007) 1.38
Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes. Addict Biol (2010) 1.38
Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J Neurosci (2008) 1.35
Translational and reverse translational research on the role of stress in drug craving and relapse. Psychopharmacology (Berl) (2011) 1.33
Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med (2009) 1.31
Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl) (2003) 1.31
Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) (2003) 1.28
Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res (2004) 1.26
Blunted rostral anterior cingulate response during a simplified decoding task of negative emotional facial expressions in alcoholic patients. Alcohol Clin Exp Res (2007) 1.26
Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. Eur J Neurosci (2005) 1.25
Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence. Neurosci Lett (2004) 1.24
Neuroendocrine, cognitive and structural imaging characteristics of women on longterm sickleave with job stress-induced depression. Biol Psychiatry (2006) 1.23
Rescue of infralimbic mGluR2 deficit restores control over drug-seeking behavior in alcohol dependence. J Neurosci (2013) 1.22
Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry (2010) 1.21
Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol Psychiatry (2006) 1.20
Neuroplasticity in brain reward circuitry following a history of ethanol dependence. Eur J Neurosci (2008) 1.19
Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev (2009) 1.18
Functional CRH variation increases stress-induced alcohol consumption in primates. Proc Natl Acad Sci U S A (2009) 1.18
Depletion of endogenous spinal 5-HT attenuates the behavioural hypersensitivity to mechanical and cooling stimuli induced by spinal nerve ligation. Pain (2006) 1.17
Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry (2011) 1.17
Association between the recombinant human serotonin transporter linked promoter region polymorphism and behavior in rhesus macaques during a separation paradigm. Dev Psychopathol (2007) 1.16
Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology (2002) 1.16
Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference. Neuropsychopharmacology (2006) 1.16
Region-specific down-regulation of Crhr1 gene expression in alcohol-preferring msP rats following ad lib access to alcohol. Addict Biol (2007) 1.15
Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci (2003) 1.15
Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry (2010) 1.14
Dysregulation of nociceptin/orphanin FQ activity in the amygdala is linked to excessive alcohol drinking in the rat. Biol Psychiatry (2008) 1.14
The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology (Berl) (2007) 1.14
The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation. Arthritis Res Ther (2005) 1.13
Localization of the endocannabinoid-degrading enzyme fatty acid amide hydrolase in rat dorsal root ganglion cells and its regulation after peripheral nerve injury. J Neurosci (2009) 1.13
Regulation of pain sensitivity in experimental osteoarthritis by the endogenous peripheral opioid system. Arthritis Rheum (2008) 1.12
Neuropeptide Y (NPY) suppresses yohimbine-induced reinstatement of alcohol seeking. Psychopharmacology (Berl) (2009) 1.12
D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: a PET study in a receptor internalization-deficient mouse model. Neuroimage (2010) 1.12
Interactions between NPY and CRF in the amygdala to regulate emotionality. Neuropeptides (2004) 1.11
microRNA-206 in rat medial prefrontal cortex regulates BDNF expression and alcohol drinking. J Neurosci (2014) 1.11
The amygdala, panic disorder, and cardiovascular responses. Ann N Y Acad Sci (2003) 1.11
The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y and not Y receptors. Eur J Neurosci (2005) 1.10
Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2. Psychopharmacology (Berl) (2006) 1.10
Descending serotonergic controls regulate inflammation-induced mechanical sensitivity and methyl-CpG-binding protein 2 phosphorylation in the rat superficial dorsal horn. Mol Pain (2008) 1.10
Neuropeptide S facilitates cue-induced relapse to cocaine seeking through activation of the hypothalamic hypocretin system. Proc Natl Acad Sci U S A (2010) 1.10
CRH haplotype as a factor influencing cerebrospinal fluid levels of corticotropin-releasing hormone, hypothalamic-pituitary-adrenal axis activity, temperament, and alcohol consumption in rhesus macaques. Arch Gen Psychiatry (2008) 1.09
Experimental acute pancreatitis in PAP/HIP knock-out mice. Gut (2007) 1.08
Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate. Neuropsychopharmacology (2011) 1.08
Loss of metabotropic glutamate receptor 2 escalates alcohol consumption. Proc Natl Acad Sci U S A (2013) 1.07
Long-term suppression of forebrain neurogenesis and loss of neuronal progenitor cells following prolonged alcohol dependence in rats. Int J Neuropsychopharmacol (2010) 1.07
Co-treatment with riluzole and GDNF is necessary for functional recovery after ventral root avulsion injury. Exp Neurol (2004) 1.07
Gene-environment interactions and response to social intrusion in male and female rhesus macaques. Biol Psychiatry (2009) 1.07
Angiotensin-II is a putative neurotransmitter in lactate-induced panic-like responses in rats with disruption of GABAergic inhibition in the dorsomedial hypothalamus. J Neurosci (2006) 1.07
Role for substance p-based nociceptive signaling in progenitor cell activation and angiogenesis during ischemia in mice and in human subjects. Circulation (2012) 1.07
Stress-related neuropeptides and addictive behaviors: beyond the usual suspects. Neuron (2012) 1.06
Effects of early-life stress on serotonin(1A) receptors in juvenile Rhesus monkeys measured by positron emission tomography. Biol Psychiatry (2010) 1.06
Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect. Hum Mutat (2010) 1.06
Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology (2006) 1.06
Functional NPY variation as a factor in stress resilience and alcohol consumption in rhesus macaques. Arch Gen Psychiatry (2010) 1.05
The murine neurokinin NK1 receptor gene contributes to the adult hypoxic facilitation of ventilation. Eur J Neurosci (2002) 1.05
Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res (2004) 1.04
Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol Psychiatry (2008) 1.04